At the 2009 Emerson Users Exchange, Ali Afnan, senior Fellow at FDA's Center for Drug Evaluation and Research, discusses real time release, highlighting Aventis 'work with API and finished drug manufacturing (link to an interview with the chief architect of that project here. http://www.pharmamanufacturing.com/multimedia/2008/Radspinner.html
End-of-line testing isn't bad, Afnan says, but it needs to be used for different reasons. For more information, visit www.PharmaManufacturing.com.
Link to this comment:
All Comments (0)